Artificial Liver Support System Improves Short-Term Outcomes of Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Propensity Score Analysis
Table 3
Short-term survival rates for patients in different COSSH-ACLF grades.
COSSH-ACLF
Prevalence
28-day survival rate
90-day survival rate
Total (n = 790)
60.0% (474/790)
45.8% (362/790)
ACLF grade 1
58.4% (461/790)
76.1% (351/461)
61.2% (282/461)
ACLF grade 2
38.6% (305/790)
40.0% (122/305)
26.2% (80/305)
ACLF grade 3
3.0% (24/790)
4.2% (1/24)
0 (0/24)
SMT (n = 310)
59.0% (185/310)
42.3% (136/310)
ACLF grade 1
66.8% (207/310)
72.5% (150/207)
55.6% (115/207)
ACLF grade 2
30.3% (94/310)
37.2% (35/94)
22.3% (21/94)
ACLF grade 3
2.9% (9/310)
0 (0/9)
0 (0/9)
ALSS (n = 310)
65.2% (205/310)
51.0% (163/310)
ACLF grade 1
67.4% (209/310)
78.5% (164/209)
65.1% (136/209)
ACLF grade 2
29.7% (92/310)
43.5% (40/92)
29.3% (27/92)
ACLF grade 3
2.9% (9/310)
11.1% (1/9)
0 (0/9)
SMT, standard medical therapy; ALSS, artificial liver support system.
